Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS - PubMed
4 hours ago
- #Multiple Myeloma
- #Daratumumab
- #Minimal Residual Disease
- D-VRd significantly increased MRD-negative rates at both 10^-5 and 10^-6 thresholds compared to VRd in transplant-ineligible or deferred NDMM patients.
- Sustained MRD negativity (≥12 months) was significantly higher with D-VRd versus VRd at both sensitivity levels.
- Among MRD-negative patients, PFS trended favorably for D-VRd, though not statistically significant.
- D-VRd demonstrates deeper and more durable responses, improving PFS and setting a new standard of care.